menu
    • menu
    [{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Siltuximab","moa":"Il-6","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Eusa Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eusa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Siltuximab","moa":"Il-6","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eusa Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eusa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Siltuximab","moa":"Il-6","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eusa Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eusa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Approved","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"solution for infusion","sponsorNew":"Eusa Pharma \/ BeiGene","highestDevelopmentStatusID":"12","companyTruncated":"Eusa Pharma \/ BeiGene"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Aveo Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tivozanib","moa":"VEGF","graph1":"Oncology","graph2":"Approved","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"capsule","sponsorNew":"Eusa Pharma \/ EUSA Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Eusa Pharma \/ EUSA Pharma"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Siltuximab","moa":"IL-6","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Eusa Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eusa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Recordati","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Approved","graph3":"Eusa Pharma","amount2":0.84999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.84999999999999998,"dosageForm":"Infusion","sponsorNew":"Eusa Pharma \/ Recordati","highestDevelopmentStatusID":"12","companyTruncated":"Eusa Pharma \/ Recordati"}]

    Find Clinical Drug Pipeline Developments & Deals by Eusa Pharma

    Menu

    Eusa Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eusa Pharma

                            France arrow
                            PackExpo
                            Not Confirmed

                            Eusa Pharma

                            France arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Recordati

                            Deal Size : $847.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Recordati to Acquire Eusa Pharma (UK) Ltd, A Global Specialty Pharmaceutical Company Focused on Rare and Niche...

                            Details : Recordati will expand its pipeline by acquiring EUSA Pharma pipeline and enhances the breadth of indications which include Qarziba®, an anti-GD2 monoclonal antibody, Sylvant®, an anti-IL-6 monoclonal antibody, Fotivda®, an oral highly selective small ...

                            Brand Name : Qarziba

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 03, 2021

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Recordati

                            Deal Size : $847.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Eusa Pharma

                            France arrow
                            PackExpo
                            Not Confirmed

                            Eusa Pharma

                            France arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Siltuximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EUSA Pharma Enrolles First Patient in Phase 3 Clinical Trial Investigating Siltuximab in Hospitalised Patients...

                            Details : This pivotal study will evaluate the efficacy and safety of standard of care (SOC) with or without intravenous siltuximab in selected hospitalised patients with COVID-19 previously treated with corticosteroids or another respiratory virus infection.

                            Brand Name : Sylvant

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 17, 2020

                            Lead Product(s) : Siltuximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eusa Pharma

                            France arrow
                            PackExpo
                            Not Confirmed

                            Eusa Pharma

                            France arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : BeiGene

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA® (Dinutuximab Beta...

                            Details : QARZIBA® is a monoclonal antibody that is specifically directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells.

                            Brand Name : Qarziba

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 09, 2020

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : BeiGene

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Eusa Pharma

                            France arrow
                            PackExpo
                            Not Confirmed

                            Eusa Pharma

                            France arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tivozanib,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Aveo Oncology

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AVEO Oncology and EUSA Pharma Announce Annals of Oncology Publication of Data from Phase 1b/2 TiNivo Study in ...

                            Details : The Phase 2 portion of the study was designed to assess the safety, tolerability, and anti-tumor activity of the full dose and schedule of PO tivozanib, in combination with IV nivolumab.

                            Brand Name : Fotivda

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 05, 2020

                            Lead Product(s) : Tivozanib,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Aveo Oncology

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Eusa Pharma

                            France arrow
                            PackExpo
                            Not Confirmed

                            Eusa Pharma

                            France arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Siltuximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EUSA Pharma Announces FDA Approval of Phase 3 Clinical Trial for Siltuximab in Hospitalized Patients With COVI...

                            Details : Siltuximab is a monoclonal antibody that directly neutralizes interleukin (IL)-6, an inflammatory cytokine detected at elevated levels in multiple inflammatory conditions, including COVID-19. It specifically binds to IL-6, thereby inactivating IL-6 induc...

                            Brand Name : Sylvant

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 02, 2020

                            Lead Product(s) : Siltuximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Eusa Pharma

                            France arrow
                            PackExpo
                            Not Confirmed

                            Eusa Pharma

                            France arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Siltuximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EUSA Pharma and Papa Giovanni XXIII Hospital, Italy, Provide Interim Analysis Data for Siltuximab-Treated COVI...

                            Details : A third of patients with COVID-19 taking EUSA Pharma's interleukin (IL)-6 targeted monoclonal antibody siltuximab have experienced a clinical improvement, reveals a case-control trial in Italy.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 01, 2020

                            Lead Product(s) : Siltuximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Eusa Pharma

                            France arrow
                            PackExpo
                            Not Confirmed

                            Eusa Pharma

                            France arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Siltuximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EUSA Pharma and Papa Giovanni XXIII Hospital to Initiate an Observational Case-control Study of Siltuximab in ...

                            Details : The step was followed by the release of initial data from China suggesting a role of IL-6 in the development of Acute Respiratory Distress Syndrome as a result of COVID-19.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 18, 2020

                            Lead Product(s) : Siltuximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth